Cargando…
Establishment of Novel DNA Methylation-Based Prostate Cancer Subtypes and a Risk-Predicting Eight-Gene Signature
Prostate cancer (PCa) is the most common malignant tumor affecting males worldwide. The substantial heterogeneity in PCa presents a major challenge with respect to molecular analyses, patient stratification, and treatment. Least absolute shrinkage and selection operator was used to select eight risk...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7940376/ https://www.ncbi.nlm.nih.gov/pubmed/33708770 http://dx.doi.org/10.3389/fcell.2021.639615 |
_version_ | 1783661940640317440 |
---|---|
author | Zhang, Enchong Shiori, Fujisawa Mu, Oscar YongNan He, Jieqian Ge, Yuntian Wu, Hongliang Zhang, Mo Song, Yongsheng |
author_facet | Zhang, Enchong Shiori, Fujisawa Mu, Oscar YongNan He, Jieqian Ge, Yuntian Wu, Hongliang Zhang, Mo Song, Yongsheng |
author_sort | Zhang, Enchong |
collection | PubMed |
description | Prostate cancer (PCa) is the most common malignant tumor affecting males worldwide. The substantial heterogeneity in PCa presents a major challenge with respect to molecular analyses, patient stratification, and treatment. Least absolute shrinkage and selection operator was used to select eight risk-CpG sites. Using an unsupervised clustering analysis, called consensus clustering, we found that patients with PCa could be divided into two subtypes (Methylation_H and Methylation_L) based on the DNA methylation status at these CpG sites. Differences in the epigenome, genome, transcriptome, disease status, immune cell composition, and function between the identified subtypes were explored using The Cancer Genome Atlas database. This analysis clearly revealed the risk characteristics of the Methylation_H subtype. Using a weighted correlation network analysis to select risk-related genes and least absolute shrinkage and selection operator, we constructed a prediction signature for prognosis based on the subtype classification. We further validated its effectiveness using four public datasets. The two novel PCa subtypes and risk predictive signature developed in this study may be effective indicators of prognosis. |
format | Online Article Text |
id | pubmed-7940376 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-79403762021-03-10 Establishment of Novel DNA Methylation-Based Prostate Cancer Subtypes and a Risk-Predicting Eight-Gene Signature Zhang, Enchong Shiori, Fujisawa Mu, Oscar YongNan He, Jieqian Ge, Yuntian Wu, Hongliang Zhang, Mo Song, Yongsheng Front Cell Dev Biol Cell and Developmental Biology Prostate cancer (PCa) is the most common malignant tumor affecting males worldwide. The substantial heterogeneity in PCa presents a major challenge with respect to molecular analyses, patient stratification, and treatment. Least absolute shrinkage and selection operator was used to select eight risk-CpG sites. Using an unsupervised clustering analysis, called consensus clustering, we found that patients with PCa could be divided into two subtypes (Methylation_H and Methylation_L) based on the DNA methylation status at these CpG sites. Differences in the epigenome, genome, transcriptome, disease status, immune cell composition, and function between the identified subtypes were explored using The Cancer Genome Atlas database. This analysis clearly revealed the risk characteristics of the Methylation_H subtype. Using a weighted correlation network analysis to select risk-related genes and least absolute shrinkage and selection operator, we constructed a prediction signature for prognosis based on the subtype classification. We further validated its effectiveness using four public datasets. The two novel PCa subtypes and risk predictive signature developed in this study may be effective indicators of prognosis. Frontiers Media S.A. 2021-02-23 /pmc/articles/PMC7940376/ /pubmed/33708770 http://dx.doi.org/10.3389/fcell.2021.639615 Text en Copyright © 2021 Zhang, Shiori, Mu, He, Ge, Wu, Zhang and Song. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Cell and Developmental Biology Zhang, Enchong Shiori, Fujisawa Mu, Oscar YongNan He, Jieqian Ge, Yuntian Wu, Hongliang Zhang, Mo Song, Yongsheng Establishment of Novel DNA Methylation-Based Prostate Cancer Subtypes and a Risk-Predicting Eight-Gene Signature |
title | Establishment of Novel DNA Methylation-Based Prostate Cancer Subtypes and a Risk-Predicting Eight-Gene Signature |
title_full | Establishment of Novel DNA Methylation-Based Prostate Cancer Subtypes and a Risk-Predicting Eight-Gene Signature |
title_fullStr | Establishment of Novel DNA Methylation-Based Prostate Cancer Subtypes and a Risk-Predicting Eight-Gene Signature |
title_full_unstemmed | Establishment of Novel DNA Methylation-Based Prostate Cancer Subtypes and a Risk-Predicting Eight-Gene Signature |
title_short | Establishment of Novel DNA Methylation-Based Prostate Cancer Subtypes and a Risk-Predicting Eight-Gene Signature |
title_sort | establishment of novel dna methylation-based prostate cancer subtypes and a risk-predicting eight-gene signature |
topic | Cell and Developmental Biology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7940376/ https://www.ncbi.nlm.nih.gov/pubmed/33708770 http://dx.doi.org/10.3389/fcell.2021.639615 |
work_keys_str_mv | AT zhangenchong establishmentofnoveldnamethylationbasedprostatecancersubtypesandariskpredictingeightgenesignature AT shiorifujisawa establishmentofnoveldnamethylationbasedprostatecancersubtypesandariskpredictingeightgenesignature AT muoscaryongnan establishmentofnoveldnamethylationbasedprostatecancersubtypesandariskpredictingeightgenesignature AT hejieqian establishmentofnoveldnamethylationbasedprostatecancersubtypesandariskpredictingeightgenesignature AT geyuntian establishmentofnoveldnamethylationbasedprostatecancersubtypesandariskpredictingeightgenesignature AT wuhongliang establishmentofnoveldnamethylationbasedprostatecancersubtypesandariskpredictingeightgenesignature AT zhangmo establishmentofnoveldnamethylationbasedprostatecancersubtypesandariskpredictingeightgenesignature AT songyongsheng establishmentofnoveldnamethylationbasedprostatecancersubtypesandariskpredictingeightgenesignature |